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ABSTRACT
Osteogenesis imperfecta (OI) is a hereditary connective tissue disease that causes frequent fractures. Little is known about causes of
death and length of survival in OI. The objective of this work was to calculate the risk and cause of death, and the median survival
time in patients with OI. This study was a Danish nationwide, population-based and register-based cohort study. We used National
Patient Register data from 1977 until 2013 with complete long-term follow-up. Participants comprised all patients registered with
the diagnosis of OI from 1977 until 2013, and a reference population matched ﬁve to one to the OI cohort. We calculated hazard
ratios for all-cause mortality and subhazard ratios for cause-speciﬁc mortality in a comparison of the OI cohort and the reference
population. We also calculated all-cause mortality hazard ratios for males, females, and age groups (0 to 17.99 years, 18.00 to 34.99
years, 35.00 to 54.99 years, 55.00 to 74.99 years, and >75 years). We identiﬁed 687 cases of OI (379 women) and included 3435
reference persons (1895 women). A total of 112 patients with OI and 257 persons in the reference population died during the
observation period. The all-cause mortality hazard ratio between the OI cohort and the reference population was 2.90. The median
survival time for males with OI was 72.4 years, compared to 81.9 in the reference population. The median survival time for females
with OI was 77.4 years, compared to 84.5 years in the reference population. Patients with OI had a higher risk of death from
respiratory diseases, gastrointestinal diseases, and trauma. We were limited by the lack of clinical information about phenotype and
genotype of the included patients. Patients with OI had a higher mortality rate throughout their life compared to the general
population. © 2016 American Society for Bone and Mineral Research.
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Introduction
Osteogenesis imperfecta (OI) is a hereditary disorder of theconnective tissue,(1,2) with a heterogeneous clinical
presentation.(3,4) Inheritance is either autosomal dominant
(OI type I to V), due to mutations in the COL1A1 or COL1A2
genes in OI type I to IV, and IFITM5/BRIL mutations in OI type V,
or autosomal recessive, largely due to mutations in genes
involved in the posttranslational processing of collagen type 1.(1)
Severe cases are often caused by de novo mutations.(5) OI is
grouped according to clinical severity and inheritance by the
Sillence classiﬁcation (originally 1979, updated 2014).(3,4) The
mildest phenotype, type I, accounts for 71%of cases in Denmark,
and the most severe phenotype, type II, for 12% of cases.(6) The
prevalence of OI at birth is 21.8 per 100.000 and the population
prevalence is 10.6 per 100,000.(6)
A hallmark of OI is frequent fractures.(7,8) Although the skeletal
consequences of OI are well described, less is known about other
aspects of the disease. A British study on causes of death in
patients with OI reported 79 deaths between 1980 and 1995 in a
cohort of 1297 patients identiﬁed via a survey and clinically
diagnosed with OI.(9) The authors identiﬁed respiratory tract
infection as the most frequent cause of death in OI, and found a
mean age at death of 6.2 years in the severe phenotypes and
63.5 years in themilder phenotypes.(9) It is feasible that OI causes
diseases to other organ systems, because collagen type 1—the
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affected collagen in OI—is the most abundant collagen in the
human body.(10,11)
For governance, Denmark has a long-standing tradition for
registering individual-level information on among others; Danish
births, deaths, migration, and all contacts to the healthcare
system. Since 1977 this information has been available for
research.(12) The National Patient Register (NPR), housed under
the National Board of Health, have registered referral diagnosis
(from the primary healthcare system to the hospital case system,
or between hospital wards) and discharge diagnosis for all in
hospital stays since 1977, and for all outpatient clinic and
emergency room visits since 1995 and onward, on an individual
level.(12) The data entered into the registers is done, asmandatory
byDanish law, onahospital level, basedonadministrativedataon
patient’s municipality, identiﬁcation of hospital wards, date and
time of activity, and clinical data based on a physicians evaluation
of the patient. NPR has coverage above 99% for all hospital
contacts in Denmark. Moreover, the Danish healthcare system is
with fewminor exceptions—uniform, tax-ﬁnanced, and covers all
residents. The Danish Cause of Death register covers all deaths in
Denmark since 1977.(13) The Civil Registration System contains a
unique personal identiﬁer that allows for record linkage through
out the Danish health and civil registers.(14) Everyone born, or
having an address in Denmark, have since 1968 been allocated a
unique personal identiﬁer, a CPR number. The Civil Registration
System includes references to parents and spouses, making it
possible to establish the family unit.(14)
Study objectives
Our aim was to calculate the risk of death, identify the main
cause of death, and calculate the median survival time in
patients with OI compared to the general population. We
hypothesized that patients with OI have increased all-cause
mortality and thus reduced median survival time. Furthermore,
we hypothesized that patients with OI have increased risk of
death from respiratory and cardiovascular diseases. Better
knowledge about life expectancy and the primary causes of
death in patients with OI, will give insight into diseases that need
attention in the care for patients with OI.
Subjects and Methods
Study design
The present study is a national population-based and register-
based cohort study, including all registered patients with OI in
the Danish health registries and a reference population of
randomly selected persons, matched on age and gender to each
OI patient (5:1) from the Danish Personal Registration System
(the CPR register).
Data sources
Statistics Denmark Division of Research Services supplied anony-
mized data (Project reference number: 704542). The Statistics
Denmark Division of Research Services administrates the different
health registers used in this study. Statistics Denmark is a state
institution under the Ministry of Social Affairs and the Interior.
Study participants
Patients
All patients registered in NPR with International Classiﬁcation of
Diseases, Eighth Revision (ICD-8) (756.59) or ICD 10th revision
(ICD-10) (Q78.0) diagnosis of OI between January 1, 1977, and
December 31, 2012, were included in the study.
Reference population
Five persons, randomly selected from the Danish Civil Registra-
tion system (CPR), were matched to each patient with OI by
gender, birth year, and birth month. Reference individuals could
not be ﬁrst-degree or second-degree relatives to patients with
OI, nor could they later acquire an OI diagnosis.
Outcome, variables, and data sources
Information on primary cause of death, time, and place of death
was extracted from the Danish Cause of Death Register. ICD-8
diagnoses (1977 to 1993) were transformed into ICD-10 chapter
codes (I to XXII). If fewer than three persons had died from
diseases within an ICD-10 chapter, death was recoded as being
from “other causes” to maintain patient conﬁdentiality.
We extracted comorbidity data from the NPR for inpatient
stays, outpatient visits, and emergency visits and included both
primary and supplementary diagnoses. This information was
used to calculate the maximum Charlson comorbidity index
(CCI) for each participant, as described using data from the
NPR.(15) Data on migration were extracted from the Danish Civil
Registration system.
Exposure
Because OI is a congenital disease, we deﬁned all identiﬁed
patients to have been at risk since birth, even if their diagnosis
was nominally made at a later stage. Patients born prior to 1977
had to be alive until at least January 1, 1977, to be able to be
featured in the registries, some patients will have suffered from
OI, but died prior to the observations period. The observations
time ended at death, December 31, 2013, or when a person
emigrated from, without returning to, Denmark.
Confounders
We corrected for comorbidity as a confounder of all-cause
mortality. We did not control formajor fractures, because this is a
pathognomonic feature of OI and would thus be correcting
for the exposure. Patients with OI are often treated with
bisphosphonates. Bisphosphonate treatment reduces mortality
in osteoporotic women.(16) We cannot correct for this possible
confounder, because we have no information about cumulative
dosages in the two cohorts.
Because data were available from the Cause of Death register
until December 31, 2013 (1 year more than the NPR data), we
cannot rule out that a reference person could have been
diagnosed with OI in the last year of observation, but ﬁnd this
unlikely.
We corrected for gender and calendar year of birth as
confounders of life expectancy and risk of death. We did not
correct for place of birth or last known residence (rural or urban),
as this is not possible through the given data sources.
Statistical analysis
Data are presented descriptively using Kaplan-Meier survival
estimate curves to show survival for both the OI and reference
cohort. We present hazard ratio (HR) and subhazard ratios (SHRs)
with 95% conﬁdence intervals (CI) between the OI and reference
cohorts, and mean SD or median (range) as appropriate.
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A p value<0.05 was considered statistically signiﬁcant. HRs and
SHRs were signiﬁcant when the 95% CI did not include 1.00.
All statistical analysis were done using Stata 14.1 (Stata
Corporation, Inc., College Station, TX, USA), with a user-written
program for the Laplace regression.(17)
The all-cause mortality hazard was not proportional over time
between the two cohorts. Therefore, we stratiﬁed the data into
ﬁve age groups, and applied a parametric exponential piecewise
regression model. The age groups were ages 0 to 17.99 years,
18.00 to 34.99 years, 35.00 to 54.99 years, 55.00 to 74.99 years, or
>75.00 years. We calculated the gender-speciﬁc all-cause
mortality HR using the same model, but including either men
or women.
To compare the all-causemortality HR for theOI and reference
cohorts by age group, we ﬁtted a Cox proportional hazards
regression model including only participants within each age
group running the analysis for each age group alone.
We present the all-cause mortality HR for the total population
and by age and gender, both unadjusted and adjusted for
differences in CCI.
Between the OI cohort and the reference population SHRs
for each primary cause of death were calculated using the Fine
and Gray(18) competing risk regression model for each ICD-10
chapter.
We estimated Schoenfeld residuals for the piecewise
exponential regression models, and evaluated goodness of ﬁt
by visually estimating the Cox-Snell residuals after plotting the
estimated cumulative hazard of the Cox-Snell residual to a
Nelson-Aalen graph. The Cox proportional hazards models were
tested using Stata’s built-in test of the proportional-hazards
assumption (phtest). We tested the assumptions of the
competing risk regression model by determining whether the
covariates varied signiﬁcantly over time.
We used Laplace-regression for censored data, as described
by Bottai and Zhang,(17) to determine the difference in median
survival time between the OI and reference cohorts.
The CCI, place of death, and number of registered causes of
death were summarized for the OI and reference cohorts, and
the differences were tested using Pearson’s chi square test.
A sensitivity analysis was performed leaving all participants,
only registered in the NPR with a referral diagnosis, and their
matched counterparts in the reference population out of the
analysis.
Ethical considerations
The study was approved by the Danish Data Protection Agency.
All data were deidentiﬁed by the data provider. The study was
not a clinical trial, and thus did not require ethics committee
approval.
Results
We identiﬁed 687 patients (379 females, 55.2%) (25,615 person
years at risk) with OI from the NPR. We identiﬁed 366 patients,
born after 1977, of which 14 patients were only registered in the
NPR with a referral diagnosis (ie, they had been referred from
their general practitioner or from other hospitals (where the
referral diagnosis [OI] had been registered in the NPR) without a
discharge diagnosis being registered yet, in the NPR). In this
period, themedian annual incidence of OI was 15 (range, 5 to 24)
per 100,000 births; 112 patients died during the observation
period.
In the reference population, 3435 persons (1895 females)
(132,131 person years at risk) were included in the study, and
1830 persons were born after 1977. During the observation
period, 257 people died. There were signiﬁcantly more
non-European immigrants in the reference population (4.7%)
than in the OI cohort (2%), p¼ 0.001. Population characteristics
are summarized in Table 1.
The two groups differed in the number of causes of death
registered (p< 0.001), where 13.4% (n¼ 15) of the deceased in
theOI cohort but 34.0% (n¼ 87) of the deceased in the reference
population had only one cause of death registered, but not in
the place of death. The overall CCI was signiﬁcantly higher
(p¼ 0.003) in the OI cohort, where more patients than controls
had a CCI above 0. The age-speciﬁc comorbidity distributions are
shown in Fig. 1.
Kaplan-Meier survival estimate curves for the total population
from birth and for the subpopulation born after 1977 show a
more rapid decline in survival in the OI cohort (Fig. 2). The
median time of survival for males with OI was 72.4 years (95% CI,
68.8 to 77.7) versus 81.9 years (95% CI, 79.3 to 84.3) for men in
the reference population (p< 0.001). The median survival time
for females with OI was 77.4 years (95% CI, 74.6 to 79.8) versus
84.5 years (95% CI, 83.0 to 86.2) in the reference population
(p< 0.001). Only truncated median survival time, with a
maximumof 35 years, could be calculated for the subpopulation
born after 1977. Only males with OI, born after 1977, showed
attrition, with approximately 85% still alive at the end of the
observation time.
The all-cause mortality HR in the OI and reference cohorts is
summarized in Table 2. After correcting for differences in
comorbidity and gender, we found an all-cause mortality HR of
2.9 (95% CI, 2.3 to 3.6) in patients with OI compared to the
reference population. For women with OI, the HR was 2.4 (95%
CI, 1.8 to 3.3) and for men with OI 3.7 (95% CI, 2.6 to 5.2),
compared to the reference population. Unadjusted HR for
all-cause mortality was 2.9 (95% CI, 2.3 to 3.6) for the total
population, 2.5 (95% CI, 1.8 to 3.3) for women and 3.5 (95% CI,
2.5 to 5.0) for men.
Table 1. Characteristics of Patients With Osteogenesis Imper-
fecta and the Reference Population, Total Person Time at Risk,
and Median Survival Time From Kaplan-Meier Estimates
Osteogenesis
imperfecta
Reference
population
Total population (n) 687 3435
Females (n) 379 1895
Males (n) 308 1540
Total analysis time (years) 25615 132131
Person time at risk (years)
Age 0–18 11464 58810
Age 18–35 7009 35783
Age 35–55 4863 24520
Age 55–75 2050 10985
Age >75 229 2033
Median survival time (years)
Males 72.4 (95% CI,
68.8–77.7)a
81.0 (95% CI,
79.3–84.3)
Females 77.4 (95% CI,
74.6–79.8)a
84.5 (95% CI,
83.0–86.2)
aMedian survival time signiﬁcantly lower than for the reference
population (p< 0.001).
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When comparing the two cohorts by age group, we found an
increased all-cause mortality HR for the OI cohort using the
comorbidity-adjusted and the unadjusted Cox proportional
hazards model.
Age-speciﬁc all-causemortality HR between the OI cohort and
the reference population is summarized in Table 2.
Primary causes of death are summarized in Table 3. OI
(ICD-10 chapter 17) was reported as the primary cause of
death in a total in 32 cases. The 15 patients with OI, who died
before the age of 1 year, and the 19 who died before the age
of 6 years, had OI as the primary cause of death. Cardiovascular
diseases (ICD-10 chapter 9) and neoplasms (ICD-10 chapter 2)
were the most frequently reported primary cause of death in
both patients with OI and the reference population. SHRs were
similar in the two groups, except that patients with OI had an
increased SHR of 3.1 (95% CI, 1.4 to 6.9) for deaths caused by
respiratory diseases (ICD-10 chapter 10, including pneumonia,
inﬂuenza, and chronic obstructive pulmonary disease in acute
exacerbation), an increased SHR of 4.2 (95% CI, 1.6 to 10. 8) for
deaths due to digestive illnesses (ICD-10 chapter 11, including
gastrointestinal ulcerations and liver disease) and an increased
SHR of 4.7 (95% CI, 1.4 to 16.3) for deaths due to external
forces of morbidity and mortality (ICD-10 chapter 20, including
death due to trauma and can be regarded as deaths associated
with fractures).
Discussion
In this national register-based, cohort study we found the
all-cause mortality among patients with OI was nearly three
times that of an age- and gender-matched reference population.
The median survival time in the OI cohort was 72.4 years for
males (compared to 81.5 years in the reference population) and
77.4 for females (compared to 84.5 in the reference population).
Apart from OI itself, the most frequently reported causes of
death in both patients with OI and the reference population
were cardiovascular disease and neoplasms. Patients with OI
had an increased risk of death due to respiratory diseases,
gastrointestinal diseases, and trauma compared to the reference
population.
The relatively high median survival time, in our study, is
inﬂuenced by the survival bias introduced into the data, because
patients had to be alive at least until 1977, or born thereafter, to
be featured in the registers. We found an increased risk of death
during the early years of life for patients with OI and must
assume that this risk was equally increased for participants born
before 1977.
No previous studies have compared the risk of death for
patients with OI and a reference population representative of
the general population. We used the Danish NPR to identify
cases of OI. There is no information about the speciﬁcity,
sensitivity, positive predictive value, or negative predictive value
of having an ICD-8 or ICD-10 diagnosis for OI in the register and
actually having OI. The overall positive predictive value of any
diagnosis in the NPR is above 95%.(19) We cannot rule out
misclassiﬁcation of the patients, but the number of identiﬁed
cases ﬁts the estimated number of expected cases based on the
population prevalence of 10.6 out of 100,000 persons, reported
by Andersen and Hauge in 1989.(6) The number of contacts with
a given diagnosis in the NPR will increase the likelihood of a
patient suffering from the given diagnosis. However the OI
cohort was open, and participants entered (diagnosed at any
point in life) and left (died or migrated) the cohort during the
entire observations period, and therefore the number of
registered contacts, with an OI diagnosis, in the NPR is not a
good estimate of the likelihood of the diagnosis. When
performing the sensitivity analysis, the HR did not change
signiﬁcantly. This further increases the likelihood that the
participants in our study were indeed patients with OI.
All our data for both the patient cohort and the reference
population were extracted from the same registers. Our patient
cohort did have a higher risk of death due to respiratory diseases
than the reference population, but only 10 of 112 (8.9% of total
Fig. 1. Distribution of CCI by age in the reference population and in the patient cohort with OI. The distribution of CCI scores per decade of the
participant’s maximum age at the end of the observational period. CCI¼Charlson comorbidity index; OI¼ osteogenesis imperfecta.
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deaths) deaths were due to this cause. This differs from the 57%
of patients who died from respiratory tract infections reported
by McAllion and Paterson.(9) One explanation could be that we
only used information available in the Danish Cause of Death
register that relies on death certiﬁcates, whereas McAllion and
Paterson(9) also included information from postmortem reports,
relatives, and the OI patient organization. Their methods are
likely to be more prone to recall bias than our register-based
approach. Furthermore the McAllion and Paterson study(9) was
not population based, and included 38 out of 79 patients with
type III OI, adding to 48% of the participants. The remaining
patients were clinically diagnosed with type IV or type I OI. Thus,
most of the patients had moderate to severe phenotypes. In
contrast, we would expect that a total of 24% of our cohort had a
moderate or severe phenotype. Thus, the differences in casemix
between the present study and the McAllion and Paterson
Fig. 2. Kaplan-Meier survival curves for males and females in the patient cohort with OI and the reference population, for total population (upper
graphs) and for those born after 1977 (lower graphs). Patients with OI had higher risk of early mortality, especially for males. OI¼ osteogenesis
imperfecta.
Table 2. All-Cause Mortality for Patients With OI and the Reference Population, Followed From Birth and Including All Individuals
OI cohort versus
reference
population,
unadjusted
OI cohort versus
reference
population,
adjusted for
comorbidity (CCI)
Initial
patients with
OI (n)
Deaths in OI
cohort n (%)
Reference
population
(n)
Deaths in reference
population n (%) HR 95% CI HR 95% CI
Total populationa 687 112 (16.3) 3435 257 (7.5) 2.9 2.3–3.6 2.9 2.3–3.6
Subgroup analysisb
Age 0–18 years 687 26 (3.9) 3435 c 66.1 15.7–278.7 68.1 16.2–287.3
Age 18–35 years 486 6 (1.2) 2520 c 15.3 3.1–75.9 15.5 3.1–76.8
Age 35–55 years 326 18 (5.0) 1628 30 (1.8) 3.0 1.7–5.5 3.0 1.7–5.3
Age 55–75 years 163 39 (23.9) 837 88 (10.5) 2.4 1.7–3.5 2.4 1.7–5.5
Age >75 years 38 23 (60.5) 248 135 (54.4) 2.0 1.3–3.2 2.1 1.3–3.3
Total female populationa 379 61 (16.1) 1895 164 (8.7) 2.5 1.8–3.3 2.4 1.8–3.3
Total male populationa 308 51 (16.6) 1540 93 (6.0) 3.5 2.5–5.0 3.7 2.6–5.2
Signiﬁcant 95% CI values (not including 1.00) are indicated in bold.
OI¼ osteogenesis imperfecta; HR¼hazard ratio; CCI¼Charlson comorbidity index.
aHR was calculated using piecewise exponential regression for the total population, and for subgroups including only women or men.
bFor each age group, the HR was calculated using a Cox proportional hazards regression model, including only the individuals within each age group.
cNot disclosed to maintain patient conﬁdentiality due to low number of cases.
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study(9) may explain the difference in the primary causes of
death.
Earlier studies have shown a tendency for common causes
of death (eg, myocardial infarction) to be overdiagnosed, and
rare causes (eg, cerebral hemorrhage and intestinal thrombo-
sis) to be underdiagnosed in the Danish Cause of Death
Register.(20) Possible misclassiﬁcation or discontinuity in the
Danish Causes of Death Register of the registrations of
underlying causes of death has no impact on the results of the
all-cause mortality.(13)
Insufﬁcient data in the national register prevented us from
grouping patients according to the Sillence classiﬁcation, and
no information on patient genotype was available either. We
found, however, that 24 of the OI patients followed from birth
(born after 1977) had died. In 19 of these, OI was reported as
the primary cause of death and 15 of the patients died shortly
after birth. The mean age at death has been reported to be
lower in the group of patients with the most severe OI
phenotype.(9) According to the prevalence of the subtypes
reported by Andersen and Hauge,(6) we would expect that 76
persons in our cohort would have type II OI. Type II OI would
be expected to be uniformly lethal, either prenatally or in the
ﬁrst weeks of life. Assuming that patients who die before their
10th birthday may have the most severe phenotypes of OI,
many of those who die in their ﬁrst weeks of life are likely to
have type II OI. Neonate survival has improved over time, in
part due to better pediatric care. The calendar year of birth for
patients who died before 10 years of age and for those who
died shortly after birth, in our study, was evenly distributed
across the observation time (1977 to 2013). This suggests that
early patient death may be due to a more severe phenotype,
where the advances in pediatric and neonatal care did not
alter the outcome. Due to the low number of yearly events, we
cannot disclose the number of deaths per year for the patients
who die prior to turning 10 years old and live past the ﬁrst
weeks after birth. But seven patients died from 1977 to 1994
and three patients died from 1995 to 2013, suggesting an
effect of the institution of bisphosphonates and a multidisci-
plinary team approach in the treatment of the most severe
nonlethal OI phenotypes.
We adjusted for between-group differences in CCI, because
higher CCI is a predictor of worse outcome or earlier death.(21)
However, the all-cause mortality HR, whether adjusted for
comorbidity or not, was similar between the two populations,
indicating that the diagnosed comorbidity in the patients with
OI was not a strong predictor of death in the OI cohort. It is
more likely for patients with OI to receive hospital care than for
the general population, who may contact their general
practitioner (GP) and thus not have their disease recorded
in the NPR. The difference in CCI between the two groups
could be a result of surveillance bias and Berkson’s bias in the
OI cohort.
The OI patients had an increased risk of death due to
gastrointestinal disease compared to the reference population.
One explanation could be increased use of nonsteroid anti-
inﬂammatory drugs in the patient cohort, as pain is a hallmark of
OI. Mild analgesics (paracetamol and ibuprofen) are sold over
the counter in Denmark and are thus not registered in
prescription databases. Concerns have been raised regarding
colon, gastric, and esophageal cancers in patients with OI, even
though there have been reports of both higher and lower
risks.(22) Available register data, however, do not allow us to look
at any additional granulation in the gastrointestinal (GI) diseases
that caused death.We did, however, not see any increased risk of
death due to cancers in the OI cohort.
Mortality due to cardiovascular diseases was similar among OI
patients and the reference population. We cannot rule out that a
lack of power, due to relatively few events, caused a type II error,
thus masking a higher risk of cardiovascular disease in patients
with OI.
The lack of detailed information on genotype, phenotype,
and on what basis the OI diagnosis was made in the national
Table 3. Main Causes of Death for Patients With OI and the Reference Population (Followed From Birth and All Participants Included),
and Sub-HRs for OI Compared to the Reference Population
OI versus
reference
population
Cause of death (ICD chapters)
Deaths in OI cohort
n (%)
Deaths in reference
population n (%) Sub-HR 95% CI
Congenital malformations, deformations and
abnormalities, including OI
32 (4.7) TFE NA NA
Diseases of the circulatory system 20 (2.9) 66 (1.9) 1.5 0.9–2.5
Neoplasms 15 (2.2) 84 (2.6) 0.8 0.5–1.4
Diseases of the respiratory system 10 (1.5) 15 (0.4) 3.1 1.4–6.9
Diseases of the digestive system 9 (1.3) 8 (0.2) 4.2 1.6–10.8
External causes of morbidity and mortality 5 (0.7) 5(0.1) 5.7 1.4–16.3
Diseases of the nervous system 4 (0.6) 9 (0.3) 2.1 0.6–6.6
Other symptoms, signs, and abnormal clinical and
laboratory findings
4 (0.6) 12 (0.4) 1.1 0.3–4.0
Mental and behavioral disorders 3 (0.4) 18 (0.5) 0.8 0.2–2.5
Endocrine, nutritional, and metabolic diseases TFE 10 (0.3) NA NA
All other primary causes of death 7 (1.0) 24 (0.7) NA NA
Signiﬁcant estimates, ie, 95% CI, do not include 1.00 and are in bold.
OI¼osteogenesis imperfecta; HR¼hazard ratio; ICD¼ International Classiﬁcation of Diseases; TFE¼ too few events to report to ensure anonymity of
the participants (deaths grouped in the death due to other causes group); NA¼not applicable.
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registers is a limitation of our study. Furthermore, treatments
for common diseases and survival rates will have improved
during the lifetime of our study population. We tried to limit
this inﬂuence by matching for birth year and month. Because
OI is a genetic disorder, a possible confounding hereditary
factor would be overrepresented in certain families, thus
increasing or decreasing the baseline hazard for some OI
patients, but data on family lines were not available for
analysis and we could not correct for this potential bias. We
are limited by the relatively small numbers of deaths, which
can increase the risk of showing signiﬁcantly different
mortality rates between the two groups that are only due
to chance. The mortality patterns found were biologically
plausible; higher neonatal and childhood mortality suggested
more severe OI phenotypes, and the increased risk of death for
OI patients caused by respiratory and gastrointestinal diseases
and trauma throughout life. The national registers used in this
study have coverage above 99%(13,15) in a country with a
uniform tax-ﬁnanced healthcare system, and have complete
long-term follow-up further strengthening the results.
We conclude that patients with OI have increased all-cause
mortality rates, with a higher risk of death due to respiratory
diseases, gastrointestinal diseases, and trauma (bone frac-
tures). The shorter survival of patients with OI may be due to
increased risk of neonatal death associated with more severe
OI phenotypes, and to increased risk of death throughout life.
Further studies should explore underlying causes of death and
the association between genotype/phenotype and risk of
death.
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